Who won Boosting innovation through better integration of fragmented health… 2025? 78 companies funded
- 5funded projects
- €117.2MEU contribution
- 78companies, 25 SMEs
- 23countries
Grant topic: Boosting innovation through better integration of fragmented health R&I efforts
The European Commission funded 5 projects under the Horizon Europe topic HORIZON-JU-IHI-2025-09-02-single-stage, with €117.2M in total EU contribution. 78 private companies from 23 countries took part, and 25 of them are SMEs. Below is who they are, what they are building, and how much each received.
At a glance
- Funded projects: 5
- Total EU contribution: €117.2M
- Of which to companies: €41.7M (36%)
- Companies / of which SMEs: 78 / 25
- Average consortium size: 32.0 organisations
- Projects coordinated by a company: 2 of 5
- Top countries (company participations): Germany (14), the Netherlands (10), the United Kingdom (9), Switzerland (7)
Companies that received funding
GE Healthcare Magyarorszag Kft.
Budapest, Hungary
Received €6.5M as a participant in COMPASS: Cardio-Oncology Multidisciplinary Patient ASsistance Solution (2026-03 to 2031-02).
Philips Medical Systems Nederland BV
Best, the Netherlands · project coordinator
Received €4.3M as a coordinator in SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care. (2026-01 to 2030-12).
Siemens Healthineers AG
Forchheim, Germany
Received €3.7M as a participant in ACCESS AD: Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment (2026-01 to 2030-12).
Demcon Curix BV
Enschede, the Netherlands · SME
Received €3.2M as a participant in SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care. (2026-01 to 2030-12).
Philips Medical Systems Dmc GmbH
Hamburg, Germany
Received €3.1M as a participant in SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care. (2026-01 to 2030-12).
Philips GmbH
Hamburg, Germany · website
Received €2.2M as a participant in PreciseOnco: The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients (2026-01 to 2030-12).
Yaskawa Europe Robotics, Razvoj In Proizvodnja Robotov, d.o.o.
Kocevje, Slovenia
Received €1.9M as a participant in SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care. (2026-01 to 2030-12).
Quantum Surgical
Montpellier, France · SME
Received €1.7M as a participant in PreciseOnco: The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients (2026-01 to 2030-12).
caresyntax GmbH
Berlin, Germany
Received €1M as a participant in SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care. (2026-01 to 2030-12).
Igea SpA
Carpi, Italy · SME · website
Received €1,000K as a participant in PreciseOnco: The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients (2026-01 to 2030-12).
Hict
Gent, Belgium · SME
Received €881K as a participant in COMPASS: Cardio-Oncology Multidisciplinary Patient ASsistance Solution (2026-03 to 2031-02).
Fwdfaster Ai Research BV
Utrecht, the Netherlands · SME
Received €853K as a participant in COMPASS: Cardio-Oncology Multidisciplinary Patient ASsistance Solution (2026-03 to 2031-02).
Also funded: ZABALA Innovation Consulting SA (ES), Philips France (FR), Atrys Health SA (ES), Medtronic Iberica SA (ES), Muhdo Health Ltd (UK), Genomate Health Hungary Kft. (HU), Datawizard SRL (IT), Oldelft BV (NL), Bridg OÜ (EE), Surgical Science Sweden AB (SE), Positrigo AG (CH), SYREON Kutato Intezet Korlatolt Felelossegu Tarsasag (HU), Philips Belgium Commercial (BE), Us4us sp. z o.o. (PL), Multiverse Computing SL (ES), Themi Consulting BV (BE), Telicent LTD (UK), Iaroca AB (SE), ECG Médica S.L. (ES), Arma Biosciences Inc. (CA), Neotiv GmbH (DE), Aktiia SA (CH), Spear UG (haftungsbeschrankt) (DE), Bracco Suisse SA (CH), Pfizer Pharma GmbH (DE), HitGen Inc (CN), Nuvisan Icb GmbH (DE), Astrazeneca Uk Limited (UK), Chemspace Limited Liability Company (UA), Astrazeneca AB (SE), Abcam Limited (UK), Vernalis (r&d) Limited (UK), Enamine Germany GmbH (DE), Thermo Fisher Scientific (bremen) GmbH (DE), Pfizer Inc (US), Novo Nordisk AS (DK), IBM Israel - Science and Technology Ltd (IL), Pfizer R&D UK Limited (UK), Philips Electronics Nederland BV (NL), Yaskawa Europe GmbH (DE), and 26 more.
The funded projects
LIGAND-AI: Protein-ligand data generation at scale to support computational hit finding and optimization
€29.9M EU contribution · 22 partners · 2025-11 to 2030-10 · coordinated by Structural Genomics Consortium Lbg (UK)
The ability to discover and optimize small-molecule ligands by using innovative physics-based, machine learning (ML) and artificial intelligence (AI) approaches would transform and democratize the discovery of new small molecule drugs and related research tools (chemical probes), with important implications for the development of new medicines for rare and pediatric diseases, cancer, and women’s health.
COMPASS: Cardio-Oncology Multidisciplinary Patient ASsistance Solution
€28.7M EU contribution · 64 partners · 2026-03 to 2031-02 · coordinated by King's College London (UK)
The rise in cardiovascular disease among cancer patients and survivors, due to treatment side effects, poses a significant challenge to patient outcomes and healthcare systems. Managing cardiotoxicity is difficult due to its delayed onset and lack of reliable biomarkers, often requiring dose reduction or discontinuation of cancer treatment, which may compromise its effectiveness.
SEISMIC: SEamless Integration of image guidance to break down the barrierS and enhance the efficiency of Minimally Invasive and hybrid neurosurgical Care.
€23.5M EU contribution · 24 partners · 2026-01 to 2030-12 · coordinated by Philips Medical Systems Nederland BV (NL)
SEISMIC aims to create a holistic approach to revolutionize neurosurgical care through seamless integration of minimally invasive surgical approaches and imaging technologies. Despite neurological conditions being the leading cause of global disease burden, minimally invasive neurosurgical techniques lag significantly behind other surgical disciplines.
ACCESS AD: Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment
€20.2M EU contribution · 36 partners · 2026-01 to 2030-12 · coordinated by Stichting Amsterdam Umc (NL)
Alzheimer’s disease (AD) is a growing public health challenge in Europe’s ageing population. While Disease Modifying Therapies (DMTs) bring new therapeutic potential, fragmented care pathways, unequal diagnostic access, and healthcare limitations threaten their effectiveness and scalability.
PreciseOnco: The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients
€14.9M EU contribution · 14 partners · 2026-01 to 2030-12 · coordinated by Philips Medical Systems Nederland BV (NL)
Every year, millions of people around the world face a cancer diagnosis, and for many of them, precise and minimally invasive treatments offer the best hope for recovery. However, delivering these treatments accurately—especially deep inside the body—remains a major challenge.
What the winning consortia had in common
- Consortia averaged 32.0 organisations, and companies held 80 of 160 seats (50%).
- 31% of company seats went to SMEs, so smaller firms clearly had room in these consortia.
- 2 of 5 projects were coordinated by a company; the rest were led by universities, research organisations or public bodies.
See the original call on Grantalist.
Source: CORDIS Horizon Europe open data, © European Union, reused under CC BY 4.0. Figures are the EU contribution recorded at grant signature; data as of 2026-08-28.